Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,644,695
-
Total 13F shares
-
7,037,339
-
Share change
-
+7,037,339
-
Total reported value
-
$79,798,000
-
Price per share
-
$11.34
-
Number of holders
-
43
-
Value change
-
+$79,798,000
-
Number of buys
-
43
Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q2 2020
As of 30 Jun 2020,
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,037,339 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Polaris Venture Management Co. V, L.L.C., RA CAPITAL MANAGEMENT, L.P., CITADEL ADVISORS LLC, BlackRock Inc., Invesco Ltd., ArrowMark Colorado Holdings LLC, PURA VIDA INVESTMENTS, LLC, BANK OF AMERICA CORP /DE/, and ALLIANCEBERNSTEIN L.P..
This page lists
43
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.